That sucks. Well back to the drawing board.
Pimavanserin is a medication used for Parkinson’s disease. It is a selective inverse agonist of the serotonin 5-HT2A receptor.
The one that failed was a trial using it as an add-on to other antispychotics.
A second clinical trial of Nuplazid in schizophrenia patients with predominant “negative symptoms” is still ongoing. The company is also investigating the use of Nuplazid to treat dementia-related psychosis and major depressive disorder.
I dunno how likely that is, but we’ll see.